Skip to search formSkip to main contentSkip to account menu

dexniguldipine

Known as: DNIG 
Dexniguldipine is the (+)-enantiomer of the dihydropyridine derivate niguldipine. Dexniguldipine showed a binding affinity to the P-glycoprotein and… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Dexniguldipine Hydrochloride
dexamethasone/dexniguldipine/doxorubicin/vincristine

Broader (1)

niguldipine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Inflammatory myofibroblastic lung tumor transforming into intracranial desmoplastic noninfantile ganglioglioma
Rationale: Inflammatory myofibroblastic tumor (IMT) of the lung often arises from excessive inflammatory response. It is one of… 
2005
2005
Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA
Multidrug-resistant tumor cells can be resensitized by combined application of the selecting cytostatic drug and a… 
2004
2004
Reversal of multidrug resistance in friend leukemia cells by dexniguldipine-HCl
Dexniguldipine-HCl (DNIG) — a prospective clinical modulator of p170-glycoprotein (pgp170)-mediated multidrug resistance (MRD… 
2004
2004
Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial
Dexniguldipine-HCl is a new dihydropyridine compound that exerts selective antiproliferative activity in a variety of tumor… 
1999
1999
PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.
A convenient functional assay of the multidrug resistance (MDR) pump is useful for the diagnosis of MDR-1 cancers and the… 
1999
1999
The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.
1996
1996
Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies.
1996
1996
In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
The newly synthesized dihydropyridine derivative B859-35 was previously shown in vitro to be highly effective in reversing… 
1996
1996
P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A.
A series of different human MDR (multidrug-resistant) cell lines including a HeLa-MDR1 transfectant which exhibit high… 
1992
1992
MDR hamster cells exhibiting multiple altered gene expression: effects of dexniguldipine-HCl (B859-35), cyclosporin A and buthionine sulfoximine.
An actinomycin D selected, multidrug-resistant (MDR) hamster CHO subline showed strong expression of the P-glycoprotein and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)